With nearly 8,000 attendees at the Wynn & Encore in Las Vegas, AXS24 brought together the best minds in the pharmacy and pharmaceutical industries. The preeminent B2B healthcare event celebrated its 20th year of connection, education, and leadership devoted to evolving the specialty pharmacy industry.
Doceree, the leading global healthcare marketing platform building unprecedented programmatic solutions for HCP marketing, joined the call to put patients forward with the launch of Co-Pay Spark at the conference. Asembia’s Summit event creates so many learning and networking opportunities, that no one can experience it all. This crucial forum for understanding the challenges and solutions shaping the future of our industry serves a critical role.
Here are our top highlights from the AXS24:
Focused on the future
From educational sessions on biologics to the specialty pharmacy pipeline, speakers focused on improving the future state of patient services, the latest government regulations, and innovations in drug development.
“The Specialty Pharmacy Pipeline 2024: A Glimpse at What’s Ahead,” session kicked off the first day of presentations with a deep dive into novel treatments for rare diseases. Though oncology continues to lead the industry with 2,000 drugs in the pipeline, neurological drugs are beginning to draw attention with eight approved drugs in 2023.
The meteoric rise of GLP-1s and changes in drug pricing were the top concerns for many payers and providers. In the session, “Addressing Cost & Accessibility for Innovative Medicines – GLP-1s and Beyond,” Optum Rx President and COO Jon Mahrt shared how new indications could expand the applications for GLP-1s beyond diabetes and weight loss into heart disease, chronic kidney disease, and Alzheimer’s. GLP-1s were also covered in a session with IQVIA’s Vice President of Industry Relations Doug Long, who said the obesity category will have a profound effect on spending as obesity rates continue to grow.
Improving access, adherence, and outcomes
About one in four Americans struggle to pay for their medications, and when patients can’t afford their treatments, their outcomes suffer. In the “From Pipeline to Patient: Understanding the Barriers to Access in 2024 and Beyond” panel, presenters shared current challenges. Though pharmaceutical companies are making significant investments in improving patient access, increasing coverage restrictions and government regulations are adding even more obstacles to reaching affordable prescriptions.
In another session on this important topic, “The State of Patient Services Programs Serving Biopharma”, Two Labs and Clarivate shared market research that shows the importance of delivering information to improve access and understanding patient and prescriber needs.
Co-Pay Spark, powered by Doceree elevates affordability technology
Co-Pay Spark, a ground-breaking solution designed to connect healthcare providers with affordability program information for their patients debuted at AXS24. The new technology solves an important problem in healthcare by empowering HCPs, the patient’s most reliable source of information, with important information about manufacturer coupons, e-vouchers, and assistance programs offered by pharmaceutical manufacturers. The solution leverages patient-level data in a HIPAA-compliant manner to deliver messages about offsets that are triggered in real time at the points of prescription and dispense.
“Connecting patient affordability solutions to prescribers and patients is an essential part of overall adherence,” Shanna Barnes, SVP Patient Affordability Messaging at Doceree, said.
“Asembia provided a great opportunity for Doceree to demonstrate Co-Pay Spark’s ability to make the meaningful connection for services at the right time.”
Learn more about Co-Pay Spark is transforming patient affordability.
